Updated: Eli Lilly’s tirzepatide breaks into obesity market with FDA approval

Eli Lil­ly’s tirzepatide is of­fi­cial­ly en­ter­ing the mar­ket for chron­ic weight man­age­ment.

The drug­mak­er said Wednes­day that the GIP/GLP-1 re­cep­tor ag­o­nist, which is known as Moun­jaro for type 2 di­a­betes, can now be mar­ket­ed as Zep­bound for weight man­age­ment in adults with obe­si­ty or over­weight with “weight-re­lat­ed” health con­di­tions.

It is set to be avail­able in the US by the end of the year, in six dos­es with a list price of $1,059.87. Ac­cord­ing to Lil­ly, that price is about 20% low­er than the list price of a 2.4 mg dose of We­govy, No­vo Nordisk’s GLP-1 for weight loss. The list price for We­govy is $1,349.02 per pack­age, ac­cord­ing to No­vo’s web­site.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.